- Research Tracker
- Non-drug evidence map
- NAD+ precursors (nicotinamide riboside, NMN)
Supplements intended to raise NAD+ levels, such as nicotinamide riboside. This page lists the registered trials that test it, condition by condition, with each trial's status on ClinicalTrials.gov.
Trials by condition
Sorted by number of trials. Within a condition, trials with posted results come first, then completed, recruiting and active ones. The condition name opens its evidence-gap map.
What these trials measure
Primary outcomes, grouped by keyword rules: Inflammation and other biomarkers (6), Symptom severity and disease activity (3), Feasibility, adherence and safety (3), Pain (2), Cognition (2), Physical function and exercise capacity (2), Clinical events, survival and healthcare use (1), Quality of life (1), Fatigue and energy (1), Sleep (1), Heart rate, blood pressure and autonomic (1).
Names used for this class in the registry
nicotinamide riboside, nicotinamide riboside (nr), niagen, eh301 (nicotinamide riboside/pterostilbene), nad+, nmn, nicotinamide riboside 1g (oral), nmn intervention
Download all 25 trials (CSV) All non-drug classes
Related in Supplements and nutraceuticals: Vitamin D · Omega-3 fatty acids and fish oil · Probiotics, prebiotics and synbiotics · Coenzyme Q10 · N-acetylcysteine · Magnesium · Zinc · Melatonin · Creatine · Vitamin C · B vitamins and folate · Curcumin and other polyphenols · Amino acids and protein supplements · Herbal medicines and traditional formulas · Other vitamins, minerals and multivitamins · Other supplements and nutraceuticals
Source: ClinicalTrials.gov, searched 2026-11-16. Classification rules and exclusions: how this map is built.